



MEN

FIRST CANCER SITE
LEUKAEMIAS

LEUKAEMIAS
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LEUCEMIE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	18874		22800		22800		18874		13490		5371		1745		18874	22800
Person-years ▶	70293		73692		3399		13121		34317		16547		6307		70293	73692
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LEUKAEMIAS	1197	1.04	1432	1.18	235	3.93	207	0.95	594	1.05	292	1.08	104	1.12	0.68	3.02
HEAD AND NECK	55	1.17	62	1.25	7	2.82	7	0.75	27	1.14	12	1.13	9	2.61	0.11	0.17
ORAL CAVITY	15	1.35	16	1.37	1	1.74	0	0.00	5	0.90	6	2.36	4	4.71	0.06	0.06
PHARYNX	7	0.70	9	0.86	2	3.94	0	0.00	4	0.80	2	0.88	1	1.33	-0.04	-0.02
LARYNX	33	1.27	37	1.35	4	2.85	7	1.35	18	1.37	4	0.69	4	2.17	0.10	0.13
OESOPHAGUS	7	0.57	9	0.70	2	3.08	0	0.00	5	0.81	1	0.36	1	1.08	-0.07	-0.05
STOMACH	68	0.95	74	0.98	6	1.48	12	0.84	35	0.97	18	1.12	3	0.57	-0.05	-0.02
COLON RECTUM	181	1.13	213	1.26	32	3.86	25	0.83	93	1.18	43	1.13	20	1.51	0.29	0.60
COLON	122	1.11	145	1.25	23	4.08	17	0.83	61	1.13	28	1.06	16	1.73	0.17	0.40
RECTUM	59	1.17	68	1.29	9	3.39	8	0.83	32	1.29	15	1.28	4	1.01	0.12	0.20
LIVER	31	0.66	36	0.73	5	2.04	7	0.78	17	0.73	5	0.46	2	0.54	-0.23	-0.18
GALLBLADDER	5	0.39	6	0.44	1	1.44	0	0.00	5	0.79	0	0.00	0	0.00	-0.11	-0.10
PANCREAS	21	0.66	23	0.69	2	1.21	3	0.50	10	0.64	6	0.80	2	0.77	-0.15	-0.14
LUNG	255	1.25	338	1.58	83	7.66	45	1.14	125	1.23	72	1.54	13	0.84	0.73	1.68
SKIN MELANOMA	40	2.44	44	2.56	4	5.22	5	1.72	19	2.40	12	2.96	4	2.62	0.34	0.36
MESOTHELIOMA	7	1.16	9	1.42	2	6.87	0	0.00	6	2.03	1	0.68	0	0.00	0.01	0.04
KAPOSI SARCOMA	14	5.36	19	6.90	5	35.41	2	3.91	6	4.61	4	6.69	2	9.84	0.16	0.22
SOFT TISSUE	6	1.44	7	1.59	1	4.70	1	1.27	3	1.46	1	1.01	1	2.84	0.03	0.04
BONE	0	0.00	1	0.80	1	16.23	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	0.00
BREAST	5	1.99	6	2.27	1	7.72	1	2.11	2	1.61	2	3.37	0	0.00	0.04	0.05
PROSTATE	203	0.89	216	0.90	13	1.14	33	0.79	102	0.91	50	0.89	18	0.92	-0.37	-0.33
TESTIS	1	0.47	3	1.36	2	21.83	1	2.72	0	0.00	0	0.00	0	0.00	-0.02	0.01
KIDNEY AND RENAL PELVIS	55	1.54	68	1.82	13	7.33	24	3.63	20	1.14	8	0.94	3	1.01	0.28	0.41
BLADDER AND URINARY TRACT	125	0.96	158	1.15	33	4.77	23	0.91	64	0.99	28	0.92	10	0.97	-0.08	0.27
URINARY BLADDER	121	0.97	153	1.16	32	4.83	21	0.87	64	1.03	26	0.89	10	1.01	-0.06	0.29
URINARY TRACT	4	0.70	5	0.83	1	3.34	2	1.85	0	0.00	2	1.50	0	0.00	-0.02	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	23	1.71	26	1.84	3	4.37	4	1.56	15	2.25	2	0.64	2	1.85	0.14	0.16
THYROID	11	2.02	12	2.11	1	3.99	1	1.03	3	1.14	2	1.50	5	9.75	0.08	0.09
HODGKIN LYMPHOMA	6	2.21	7	2.45	1	7.53	0	0.00	2	1.54	3	4.68	1	3.67	0.05	0.06
NON-HODGKIN LYMPHOMA	25	0.75	28	0.80	3	1.78	4	0.64	11	0.67	8	1.01	2	0.73	-0.12	-0.09
MYELOMA	4	0.26	7	0.43	3	3.64	1	0.34	3	0.39	0	0.00	0	0.00	-0.16	-0.13
LEUKAEMIAS	7	0.25	10	0.34	3	1.99	1	0.18	3	0.22	3	0.47	0	0.00	-0.29	-0.26
LYMPHOID LEUKAEMIAS	1	0.07	3	0.21	2	2.76	1	0.38	0	0.00	0	0.00	0	0.00	-0.18	-0.15
MYELOID LEUKAEMIAS	6	0.49	6	0.46	0	0.00	0	0.00	3	0.49	3	1.04	0	0.00	-0.09	-0.10
OTHER LEUKAEMIAS	0	0.00	1	0.47	1	8.31	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.02
OTHER AND ILL DEFINED SITES	49	0.79	60	0.92	11	3.32	8	0.67	21	0.69	14	0.97	6	1.19	-0.19	-0.07

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

**FIRST CANCER SITE
LEUKAEMIAS**
**LEUKAEMIAS
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LEUCEMIE

POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LEUKAEMIAS	565	1.04	670	1.18	105	3.83	107	1.09	238	0.91	162	1.23	58	1.11	0.39	1.66
HEAD AND NECK	8	1.16	9	1.24	1	2.90	1	0.80	2	0.60	3	1.78	2	2.99	0.02	0.03
ORAL CAVITY	6	1.57	7	1.75	1	5.28	1	1.47	1	0.55	2	2.13	2	5.24	0.04	0.05
PHARYNX	1	0.68	1	0.65	0	0.00	0	0.00	0	0.00	1	2.83	0	0.00	-0.01	-0.01
LARYNX	1	0.61	1	0.58	0	0.00	0	0.00	1	1.27	0	0.00	0	0.00	-0.01	-0.01
OESOPHAGUS	2	0.71	3	1.02	1	6.85	1	1.96	1	0.74	0	0.00	0	0.00	-0.01	0.00
STOMACH	44	1.27	45	1.23	1	0.52	8	1.22	21	1.24	12	1.48	3	0.98	0.16	0.14
COLON RECTUM	108	1.24	116	1.26	8	1.78	17	1.07	50	1.19	27	1.27	14	1.68	0.36	0.40
COLON	80	1.27	84	1.27	4	1.24	14	1.23	37	1.23	16	1.04	13	2.14	0.30	0.30
RECTUM	28	1.15	32	1.25	4	3.14	3	0.67	13	1.10	11	1.88	1	0.44	0.06	0.11
LIVER	13	0.84	15	0.92	2	2.47	0	0.00	7	0.94	3	0.80	3	2.08	-0.04	-0.02
GALLBLADDER	12	0.96	13	0.98	1	1.48	2	0.85	5	0.82	4	1.34	1	0.87	-0.01	0.00
PANCREAS	21	0.90	21	0.86	0	0.00	3	0.73	9	0.82	6	1.05	3	1.28	-0.04	-0.06
LUNG	57	1.65	74	2.04	17	10.07	14	2.30	20	1.22	16	1.86	7	2.01	0.39	0.63
SKIN MELANOMA	15	1.50	19	1.82	4	8.56	1	0.58	7	1.49	7	2.84	0	0.00	0.09	0.14
MESOTHELIOMA	1	0.70	2	1.34	1	14.86	0	0.00	1	1.48	0	0.00	0	0.00	-0.01	0.01
KAPOSI SARCOMA	1	1.23	1	1.17	0	0.00	0	0.00	1	2.56	0	0.00	0	0.00	0.00	0.00
SOFT TISSUE	2	0.86	3	1.23	1	8.72	1	2.40	0	0.00	0	0.00	1	4.26	-0.01	0.01
BONE	1	1.44	1	1.37	0	0.00	0	0.00	0	0.00	0	0.00	1	14.57	0.01	0.00
BREAST	127	0.94	161	1.14	34	5.15	16	0.66	57	0.88	44	1.35	10	0.78	-0.13	0.33
CERVIX UTERI	5	0.70	6	0.80	1	2.63	1	0.72	2	0.57	2	1.23	0	0.00	-0.04	-0.03
CORPUS UTERI	10	0.42	13	0.52	3	2.50	1	0.22	4	0.34	3	0.52	2	0.92	-0.24	-0.20
OVARY	13	0.76	16	0.90	3	3.47	4	1.27	5	0.61	3	0.74	1	0.64	-0.07	-0.03
KIDNEY AND RENAL PELVIS	18	1.38	23	1.68	5	7.83	9	3.90	4	0.64	4	1.24	1	0.77	0.09	0.16
BLADDER AND URINARY TRACT	23	1.07	30	1.33	7	6.37	9	2.32	4	0.39	9	1.72	1	0.48	0.03	0.12
URINARY BLADDER	21	1.05	28	1.34	7	6.86	8	2.22	3	0.31	9	1.85	1	0.52	0.02	0.12
URINARY TRACT	2	1.29	2	1.23	0	0.00	1	3.66	1	1.36	0	0.00	0	0.00	0.01	0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	10	1.25	11	1.31	1	2.51	2	1.37	5	1.30	2	1.03	1	1.30	0.03	0.04
THYROID	12	1.25	13	1.30	1	2.37	4	2.43	5	1.11	1	0.42	2	1.85	0.04	0.05
HODGKIN LYMPHOMA	4	2.49	6	3.56	2	27.20	1	3.63	1	1.38	2	5.08	0	0.00	0.04	0.07
NON-HODGKIN LYMPHOMA	20	0.97	22	1.02	2	1.95	4	1.08	7	0.71	6	1.19	3	1.51	-0.01	0.01
MYELOMA	3	0.31	5	0.49	2	3.98	0	0.00	3	0.64	0	0.00	0	0.00	-0.12	-0.09
LEUKAEMIAS	3	0.21	6	0.39	3	3.95	1	0.37	1	0.14	1	0.29	0	0.00	-0.20	-0.15
LYMPHOID LEUKAEMIAS	0	0.00	2	0.29	2	5.78	0	0.00	0	0.00	0	0.00	0	0.00	-0.11	-0.08
MYELOID LEUKAEMIAS	3	0.45	4	0.57	1	2.91	1	0.82	1	0.31	1	0.61	0	0.00	-0.06	-0.05
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	35	0.81	42	0.93	7	3.12	8	1.03	17	0.83	8	0.76	2	0.47	-0.14	-0.06

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio